FORZANANO/nanopatent and other proactive NanoViricides, Inc. investors...
We are just a few weeks away from starting and completion of EbolaCide efficacy tests. First, we should soon find out who is going to be our BSL-4 partner to test EbolaCide for efficacy. Soon.
Since I do believe that NanoViricides, Inc. will soon have dramatically improved EbolaCide candidates I have, in anticipation of great efficacy results, drafted a petition to be posted in different places, government webpage. I want your opinion to improve on this petition that ultimately I hope "longs" will make it theirs.
Honorable _______,
The recent Ebola outbreak in West Africa has been the deadliest so far, per the World Health Organization (WHO). Ebola virus causes a deadly disease, with 60% to 90% of infected people dying, depending upon the strain of the virus. Fortunately, it is transmitted only through close contact with an infected person’s body fluids, and not through aerosol or the water route, thus limiting its transmission.
According to the WSJ:
Ebola’s economic impact has become so severe that the IMF is now warning that stricken countries could need emergency assistance. Guinea, Liberia and Sierra Leone have all been burning holes in their finances trying to curb the outbreak, and a dramatic downturn in trade—specifically timber and rubber—will compound those troubles.
And the NYT is along much the same lines:
Ebola — the reality and the hysteria over it — is having a serious economic impact on Guinea, Liberia and Sierra Leone, three nations already at the bottom of global economic and social indicators. Aggravating both the financial and social consequences, these countries and their frightened African neighbours are enacting concentric circles of quarantines, cutting off neighbourhoods, regions and even whole nations.
Currently, there are no licensed drugs or vaccines for Ebola, although some vaccines as well as some drug candidates have entered clinical trials.
Approximately 729 people have died and 1300 infected from Ebola virus in the current epidemic. It takes anywhere from 2 to 20 days for Ebola virus illness signs to appear after infection. In addition, the virus may persist up to 7 weeks in bodily fluids of recovered patients. Therefore, it is possible that transmission could sometimes occur far away with air travel, unknowingly.
Vaccines are 30%-50% effective on virus infected subjects and the Ebola virus is mutating rapidly, over 400 genetic modifications were found during the course of a recent study, and that is detrimental to current vaccines or future vaccines. Mutations of Ebola virus renders current vaccines ineffective. A treatment is therefore, essential.
Ebola virus infects a wide variety of human cell types, by using various attachment receptors to enter endosome structures inside cells. Upon entry, the virus binds to its cognate receptor, the Niemann-Pick C1 cholesterol transporter protein inside the late endosomes, fuses with the endosomal membrane, and thus enters the cytoplasm. It replicates, buds out of the cell, and the cycle repeats itself. The virus shuts down several of the host’s immune system defenses, and thus gains an upper hand.
“We believe that with our ‘intelligent nanomachines’ approach we have the potential to develop superior therapeutics as compared to other approaches,” said Anil R. Diwan, PhD, President of the Company.
[[[“We are happy to restart the Ebola program, considering the public health impact of the Ebola virus infection,” said Dr. Eugene Seymour, MD, MPH, CEO of the Company, adding, “We are in a strong financial position now, enabling us to work on this project while we continue to advance our FluCide™ and DengueCide™ therapies further towards clinical trials. We hope to create highly effective drugs against Ebola, similar to what we have achieved with our FluCide™ Influenza drug candidate.”]]]
FDA recently fast tracked clinical trials of Zmapp developed by Mapp Biopharmaceuticals. This experimental drug was employed under the FDA "Animal Rule " on the American/Samaritans Purse health workers infected with Ebola and will undergo clinical trials. "In a statement...the federal health agency said it would provide $24.9 million to Mapp Bio through an initial, 18-month contract. The company will make a small amount of ZMapp for early stage clinical safety studies and for non-clinical animal studies needed to demonstrate its safety and effectiveness."
NanoViricides, Inc. now has its own drug manufacturing facility that is capable of producing sufficient quantities of an anti-Ebola drug now that it is developed, for combating Ebola epidemics.
From Business Week:
Ebola Spread Poses a Security Threat, President Barack Obama told a U.N. President Barack Obama urged world leaders to step up their nations’ efforts in helping to contain the Ebola virus outbreak, warning that the spread of the disease could pose a global security threat.
Please help us urge the Food and Drug Administration (FDA) to use the Accelerated Approval pathway for approval and access to safe, effective EbolaCide treatment for Ebola virus - the leading killer of 3,000 people in West Africa, and thousands more infected according to latest estimates from the World Health Organization.
The area in triple brackets is the area that would enclose EbolaCide candidtates BSL-4 efficacy results.
The petition could be posted to the different web pages/locations on the day the EbolaCide efficacy results are released and once added to the final petition.
We are 10,000+ strong investors and when petitions, in the hundreds or thousands, hit the inbox of executives and lawmakers, they pay attention.
Nanopatent, perhaps you may want to ask Dr. Seymour if this would be ok although all we are trying to be is proactive. After all, all kinds of vaccines makers are getting funded while the Ebola virus continues to mutate. A treatment is needed and that should be EbolaCide.
By the way, in the U.S. the Enterovirus D68 has spread to 45+ states and cases of paralysis in children are now being reported, perhaps linked to the virus or strain of the virus.
